KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia.

Laura W Dillon, Jake Higgins, Hassan Nasif, Megan Othus, Lan Beppu, Thomas H Smith, Elizabeth Schmidt, Charles C Valentine Iii, Jesse J Salk, Brent L Wood, Harry P Erba, Jerald P Radich, Christopher S Hourigan

Haematologica 109(2) 401-410

PMID37534515
PMCIDPMC10828764
DOI10.3324/haematol.2023.283520
发表日期2023-08-03
摘要

摘要

The presence of measurable residual disease (MRD) is strongly associated with treatment outcomes in acute myeloid leukemia (AML). Despite the correlation with clinical outcomes, MRD assessment has yet to be standardized or routinely incorporated into clinical trials and discrepancies have been observed between different techniques for MRD assessment. In 62 patients with AML, aged 18-60 years, in first complete remission after intensive induction therapy on the randomized phase III SWOG-S0106 clinical trial (clinicaltrials gov. Identifier: NCT00085709), MRD detection by centralized, high-quality multiparametric flow cytometry was compared with a 29-gene panel utilizing duplex sequencing (DS), an ultrasensitive next-generation sequencing method that generates double-stranded consensus sequences to reduce false positive errors. MRD as defined by DS was observed in 22 (35%) patients and was strongly associated with higher rates of relapse (68% vs. 13%; hazard ratio [HR] =8.8; 95% confidence interval [CI]: 3.2-24.5; P<0.001) and decreased survival (32% vs. 82%; HR=5.6; 95% CI: 2.3-13.8; P<0.001) at 5 years. DS MRD strongly outperformed multiparametric flow cytometry MRD, which was observed in ten (16%) patients and marginally associated with higher rates of relapse (50% vs. 30%; HR=2.4; 95% CI: 0.9-6.7; P=0.087) and decreased survival (40% vs. 68%; HR=2.5; 95% CI: 1.0-6.3; P=0.059) at 5 years. Furthermore, the prognostic significance of DS MRD status at the time of remission for subsequent relapse was similar on both randomized arms of the trial. These findings suggest that next-generation sequencing-based AML MRD testing is a powerful tool that could be developed for use in patient management and for early anti-leukemic treatment assessment in clinical trials.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。